Custom antibody development

We offer world-leading antibody development platforms based on a proprietary RabMAb® rabbit monoclonal platform, a phage display platform (AxioMx), and a next-generation sequencing platform (NGS-RabMAb®)

Description

Associated products

Specifications

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Applications

Blocking

Purity

> 95
% SDS-PAGE.

Form

Liquid

Additional notes

This peptide may be used for neutralization and control experiments with the polyclonal antibody that reacts with this product and human PDE6 alpha, catalog ab5659. Using a solution of peptide of equal volume and concentration to the corresponding antibody will yield a large molar excess of peptide (70-fold) for competitive inhibition of antibody-protein binding reactions.

This protein participates in processes of transmission and amplification of the visual signal.

Involvement in disease

Defects in PDE6A are the cause of retinitis pigmentosa type 43 (RP43) [MIM:613810]. RP43 is a retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.